Clinical Trials Logo

Rejection Acute Renal clinical trials

View clinical trials related to Rejection Acute Renal.

Filter by:
  • None
  • Page 1

NCT ID: NCT05483725 Active, not recruiting - COVID-19 Clinical Trials

Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.

Start date: October 4, 2021
Phase:
Study type: Observational

Prospective observational trial to assess immunological safety (anti-HLA antibodies, donor-derived cell-free DNA) and immunological effectiveness (anti-SARS-CoV-2 IgG) of the first booster dose of SARS-CoV-2 mRNA vaccines in kidney transplant recipients at least one year from transplantation.

NCT ID: NCT04292418 Not yet recruiting - Clinical trials for Rejection Acute Renal

Predictors of Rejection in Pediatric Kidney Transplantation

Start date: May 1, 2020
Phase:
Study type: Observational

Renal transplantation is the best option among the end-stage renal disease (ESRD) treatment alternatives, It is also relatively less expensive than dialysis. Allograft rejection is a major issue in kidney transplantation. Rejection is classified as acute or chronic, cellular or antibody-mediated.Children with kidney transplants require life-long immunosuppressive therapy to prevent rejection of the allograft

NCT ID: NCT04166149 Active, not recruiting - Clinical trials for Transplant;Failure,Kidney

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

PancDX
Start date: September 1, 2019
Phase:
Study type: Observational

Donor-derived cell-free DNA (dd-cfDNA) has shown promise as an early marker for cellular injury caused by rejection. dd-cfDNA changes may also indicate other injuries that lead to progressive decline in transplant organ function associated with, in the case of kidney transplantation, the presence of interstitial fibrosis (IF) and tubular atrophy (TA) seen in biopsy specimens. Here, we will study the utility of dd-cfDNA to predict rejection in pancreas and pancreas-kidney recipients.

NCT ID: NCT03317925 Completed - Renal Transplant Clinical Trials

Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)

RETASK
Start date: July 16, 2014
Phase: N/A
Study type: Observational

In pediatric kidney transplant patients, rejection, medication toxicity and ischemia cause early and chronic renal allograft injury, which reduces graft lifespan and patient survival. Early detection of injury would facilitate prevention and treatment. The gold standard surveillance biopsy has limitations including delayed discovery of injury. No noninvasive test identifies graft injury before it is clinically apparent. This project's goal is to develop a novel early marker of subclinical graft injury to facilitate prompt recognition and treatment.

NCT ID: NCT03134625 Recruiting - Clinical trials for Kidney Transplantation

Metabolite Biomarkers Related to Acute Rejection in Kidney Transplantation

Start date: June 28, 2016
Phase:
Study type: Observational

The development of acute rejection can only be considered in cases with increasing serum creatinine in patients with kidney transplantation. However, the serum creatinine itself is not specific but also accurate for detection of acute rejection. So The specific biomarker is required for acute rejection of kidney transplant. In this study, the investigators will enroll 200 consecutive kidney transplant patients in Seoul National University Hospital and follow up. Serial collection of urine and serum will be done. Acute rejection specific urine metabolite will be found by LC MS/MS.